Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
about
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesEpidermal growth factor receptor in non-small cell lung cancerSilencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaRational design of non-resistant targeted cancer therapiesThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerComparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentLung cancer mutations and use of targeted agents in HispanicsEGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and PrognosisAfatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsNew data on clinical decisions in NSCLC patients with uncommon EGFR mutations.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceEpidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinibEffects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes.Drug Resistance to EGFR Inhibitors in Lung CancerClinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.EGFR mutations in non-small cell lung cancer: an audit from West China Hospital.Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.EGFR G796D mutation mediates resistance to osimertinib.Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR MutationEpidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma.
P2860
Q26744284-30FDFE1B-2FEB-4EFD-B0CF-E0074014615FQ26797297-DB8EE97E-7680-47A8-A217-039EE35E0B12Q28088636-A6F457EC-B2D9-4B84-B18A-B79AB82ECC49Q28547292-7DFAAC7C-92E6-4D33-B5AA-248F3F405C08Q33594692-A86214EF-E416-4F47-8F97-1E3DA14216A7Q33740707-BF61F2AE-C7DC-4E15-9879-6481A4485279Q33751194-C9A00EEB-BCDC-4235-9567-9C6B67DA13DBQ33779181-704B2C9D-2C52-4564-970B-DDFAFE46AD34Q33813089-D2C471CA-B730-437D-B826-A941488B9A1AQ35636924-56E0E730-192E-477F-ABA6-07C1CBEAAEA2Q36044399-108CD757-9572-43E1-8AAD-071E69980161Q36116376-EEA2FE23-476C-443F-B59F-A863DF21D479Q36215079-5846561B-BC3B-426E-A0E4-DD20A2EEB5DAQ36503084-265484E9-95DC-4D95-844B-639B8ECB5C0AQ36728450-F7B5FCDF-30E1-4EFD-B6A6-89F694BA14E2Q36733598-9EA16B3C-7667-4777-95DF-1EE185263062Q36834883-CD1931F0-17F2-4518-B7F7-C0A8DE099431Q37094986-197CDAD3-0642-4FCD-A222-7F94E035C6A5Q37344500-C7F991AF-95AB-4C08-930A-7B28614969E8Q37405620-483F1180-7135-4F00-991A-E25AFA6104B1Q37637905-3EF28F54-3FDB-40D1-94FE-F9E7A6DC678FQ37697306-69083474-4275-4F59-B4CA-D809DD153F13Q38222703-7498B2D2-AD32-4052-93BC-645B90844103Q38767492-80FC06C6-1205-4393-8334-2E010415E1D6Q39106800-1690F1EB-07F6-4998-B5A7-C8739DC9DE55Q39129178-D3465E8C-F109-49B3-9817-8B0198A7D5EBQ39163315-6B18810A-EC74-4A4E-B4B0-9F8E94A99111Q39651867-E2C5E1D3-30F6-40D9-8673-935A8260680EQ40218092-AD723E9A-B711-4EB2-B025-35C368E2730EQ40812047-4D2C7388-2A79-4A07-B52E-609BD62C4A4FQ41472663-C13E942A-6C6D-44D4-8365-C6132BD60C34Q41908351-E6FCEA4E-4997-43F3-85D6-D800A37134E8Q46194898-3A7827C0-60DF-4472-AE61-56E6456E1041Q47136456-30D1108F-990A-442C-917D-07191D9666E1Q47143835-FA2B074A-3B04-4220-922A-275B72ADE6FBQ47147399-E7CAEF42-0F4B-4375-9765-F1AA1BB82A19Q47261717-51AA90CA-2EE7-4D46-849D-EB7B3CD15F1AQ48472939-2CF1CB38-90B5-4D6F-9987-7534515A0CD2Q49379624-CB7C5C1A-7B2E-47A8-BE61-B7107B3C28B2Q49593937-167A7A34-8711-41DB-AD1C-4C1FA92A194B
P2860
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@en
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@nl
type
label
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@en
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@nl
prefLabel
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@en
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@nl
P2093
P2860
P50
P356
P1433
P1476
Rare EGFR exon 18 and exon 20 ...... e French ERMETIC-IFCT network.
@en
P2093
A-C Voegeli
A-M Ruppert
E Favre-Guillevin
F de Fraipont
I Nanni-Metéllus
P2860
P304
P356
10.1093/ANNONC/MDT418
P577
2013-11-26T00:00:00Z